


IMPACT OF SPECIALTY PHARMACIST INTEGRATION ON TIME TO PIMAVANSERIN MEDICATION ACCESS

Sabrina Livezey, PharmD¹ | Robert McCormick² | Nisha Shah, PharmD¹ | Josh DeClercq, MS³ | Leena Choi, PhD³ | Autumn Zuckerman, PharmD, BCPS, AAHIVP, CSP¹
¹Specialty Pharmacy, Vanderbilt University Medical Center, ²University of Tennessee College of Pharmacy, ³Department of Biostatistics, Vanderbilt University Medical Center

BACKGROUND

- Pimavanserin is the only FDA-approved treatment for Parkinson's Disease-related psychosis.¹
- Pimavanserin can be difficult to access due to insurance authorization requirements and limited distribution network requirements.
- Safety and efficacy monitoring is needed to ensure adherence and clinical benefit once therapy is initiated.
- Objective: Determine the impact of specialty pharmacist integration on time to access for pimavanserin.

Figure 1. Clinic Workflow




MD=prescribing physician; BI=benefits investigation; PA=prior authorization

RESULTS

Table 1. Sample Demographics


	Before integration % (n) N=33	After integration % (n) N=61
Age, years (mean ± SD)	70.4 ± 7.5	74.9 ± 8.8
Gender (male)	82% (27)	79% (48)
Race (Caucasian)	91% (30)	98% (60)
Insurance		
Commercial	24% (8)	16% (10)
Medicare/Medicaid	76% (25)	84% (51)
Financial assistance		
Yes	N/A	70.5% (43)
No	N/A	14.8% (9)
Data unavailable	N/A	14.8% (9)

Figure 2. Median time from treatment decision to access



↓ **21 day average decrease in time to medication access** ↑ **16% increase in pimavanserin approval** ↑ **18% increase in pimavanserin initiation**

Figure 3. Factors associated with time to access



- 23-fold increase** in odds of experiencing a longer time to access before integration.
- Government insurance associated with shorter access time.

Figure 4. Impact on approval and therapy initiation




Table 2. Pharmacist Interventions

Type of intervention	Number
Insurance approval/financial assistance	135
Medication counseling	58
Coordination of care (Provider/caregiver communication)	57
Patient monitoring	56
Side effect* management	6
Medication adherence	1

*patient-reported side effects included confusion, nausea, peripheral edema, and combative behavior

METHODS

Design Single-center, retrospective cohort
Sample Patients prescribed pimavanserin through neurology clinic from May 2016 - July 2018
Primary Outcome Medication access time, defined as days between treatment decision and insurance approval

CONCLUSIONS

- An integrated clinical pharmacist can expedite treatment access and initiation, while also providing monitoring for drug safety and efficacy.
- Further research is needed to assess clinic outcomes associated with faster access to pimavanserin.

References:
 1. Nuplazid (pimavanserin) tablets [package insert]. San Diego, CA: Acadia Pharmaceuticals Inc.; April 2016.
 Disclosures:
 Nisha B. Shah receives research support from AbbVie Inc. Autumn D. Zuckerman receives research support from Sanofi Inc. and Gilead.